<DOC>
	<DOCNO>NCT03099304</DOCNO>
	<brief_summary>The purpose study examine efficacy , safety , tolerability INCB018424 cream subject vitiligo .</brief_summary>
	<brief_title>A Study INCB018424 Phosphate Cream Subjects With Vitiligo</brief_title>
	<detailed_description />
	<mesh_term>Vitiligo</mesh_term>
	<criteria>Clinical diagnosis vitiligo . Vitiligo depigmented area include : least 0.5 % total body surface area ( BSA ) face ( 0.5 % BSA approximately equal area participant 's palm [ without digit ] ) AND least 3 % total BSA nonfacial area ( 3 % BSA approximately equal area 3 participant 's handprints [ palm plus 5 digit ] ) . Participants agree discontinue agent use treat vitiligo screen final followup visit . Overthecounter preparation deem acceptable investigator nonocclusive camouflage makeup permit . Conditions baseline would interfere evaluation vitiligo . Participants receive kind phototherapy , include tan bed . Participants dermatologic disease besides vitiligo whose presence treatment could complicate assessment repigmentation . Participants use skin bleaching treatment past treatment vitiligo pigment area . Participants receive follow treatment within minimum specified timeframes . Use biologic , investigational , experimental therapy procedure vitiligo within 12 week 5 halflives ( whichever longer ) screen . Use laser lightbased vitiligo treatment , include tan bed , within 8 week screen . Use immunomodulating oral systemic medication ( eg , corticosteroid , methotrexate , cyclosporine ) topical treatment may affect vitiligo ( eg , corticosteroid , tacrolimus/pimecrolimus , retinoids ) within 4 week screen . Use prior concomitant therapy list may interfere objective study per discretion investigator , include drug cause photosensitivity skin pigmentation ( eg , antibiotic tetracycline , antifungal ) within 8 week screen . Participants clinically significant abnormal thyroidstimulating hormone free T4 screening . Participants protocoldefined cytopenia screen Participants severely impair liver function . Participants impair renal function . Participants take potent systemic cytochrome P450 3A4 inhibitor fluconazole within 2 week 5 halflives , whichever longer , baseline visit . Participants previously receive JAK inhibitor therapy , systemic topical .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Vitiligo</keyword>
	<keyword>depigmenting disorder</keyword>
	<keyword>topical JAK inhibitor</keyword>
</DOC>